Details of the Drug

General Information of Drug (ID: DMKVP7E)

Drug Name
Apolizumab
Synonyms Remitogen; Hu 1D10; Hu1D10, PDL; SMART 1D10 MAb, Protein Design Labs; SMART anti-B cell lymphoma
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
G88KCP51RE
DrugBank ID
DB06467
TTD ID
D0W6WC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MHC class II antigen DR (HLA-DR) TTYA75N DRA_HUMAN ; 2B1F_HUMAN ; DRB3_HUMAN ; DRB4_HUMAN ; DRB5_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec;50(12):1958-63.
2 A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.